Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
CAPRCapricor Therapeutics(CAPR) Newsfilter·2024-06-28 21:00

-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA Scheduled for Q3 2024 to Discuss Options to Expedite BLA Filing- -Results to be Presented at PPMD Annual Conference on June 29 in Session titled "Approaches to Alter Progression"- SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) -- Caprico ...